A multi-specific, multi-affinity antibody platform neutralizes sarbecoviruses and confers protection against SARS-CoV-2 in vivo
Researchers at The Hospital for Sick Children (SickKids) have developed a novel antibody platform that enhances the targeting abilities of antibodies to combat SARS-CoV-2 variants. Leveraging the Multabody platform, co-developed by SickKids Senior Scientist Dr. Jean-Philippe Julien, these antibodies indicate increased potency, affording greater protection against SARS-CoV-2 viral variants. Promising lab results also show these antibodies indicate increased breadth, providing new neutralization effects against a broad spectrum of SARS viruses. This research establishes the Multabody platform as an important tool in the pandemic preparedness tool kit. The platform is currently being developed and validated in a number of therapeutic areas by Radiant Biotherapeutics, a recently established start-up company that SickKids helped to launch.
